Resources

2 Resources for

bextra

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

How Pfizer Hid a $2.3 Bill. Bextra Settlement in Plain Sight
BNET pointed out today that the announcement of Pfizer's acquisition of Wyeth formed a welcome distraction for Pfizer from the news that the company was also paying a $2.3 billion settlement to make the Department of Justice stop investigating the company's illegal promotion of discontinued Cox-2 painkiller Bextra. ...
Tags: Pfizer Inc., Settlement, Bextra, Litigation, Business Operations, Jim Edwards
Blog posts 2009-01-26
Document Shows Rogue Bextra Operation Inside Pfizer
The "information" document filed by federal prosecutors against Mary Holloway describes what appears to be a rogue sales unit inside Pfizer dedicated to selling the painkiller Bextra off-label and at unapproved doses. Holloway is believed to be a former Pfizer employee (see Peter Rost's join-the-dots conclusion) although documents in the...
Tags: FDA, Pfizer Inc., Bextra, Holloway, Sales Strategy, Federal Government, Sales Force Management, Sales, Government, Jim Edwards
Blog posts 2009-04-06

Additional Resources

Pfizer - Bextra: DOJ press conference
Justice Department Announces Largest Health Care Fraud Settlement in Its History Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON – American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay...
Tags: Settlement, Health Care, Pfizer Inc.
News items 2009-09-02
Hundreds of Attorneys, Medical Experts Gather to Discuss Implications of Bextra and Celebrex; Heavyweights to Discuss Developments, Legal Action at Mealey's Bextra and Celebrex Litigation Conference Sponsored by LexisNexis
DAYTON, Ohio -- On the heels of Vioxx litigation, legal claims surrounding prescription arthritis drugs are expected to soar following Pfizer's recent suspension of Bextra sales and continued FDA scrutiny of Celebrex. LexisNexisR U.S., a leading provider of legal, news and business information services, will host a symposium next month...
Tags: LexisNexis
Research articles 2005-04-19
Statement re Bextra.
Pfizer Statement on BextraR Valdecoxib NEW YORK, Nov. 11 -- Pfizer Inc said a New York Times article published today draws unsubstantiated conclusions about the cardiovascular safety of its COX-2 medicine Bextra and is base ...
Tags: patient, Pfizer Inc.
Research articles 2004-11-11
Doctors warn against taking painkiller Bextra
WASHINGTON AFP — Three US doctors have called for physicians worldwide to stop prescribing the pain-killing drug Bextra which is made by Pfizer, whose Celebrex drug was the subject of a separate warning. The three said in a letter to the New England Journal of Medicine, released in advance...
Tags: Agence France-Presse, Government, Pfizer Inc.
Research articles 2004-12-17
Aetna Informs Members and Physicians about Bextra
HARTFORD, Conn. -- Aetna (NYSE:AET) announced today it is contacting more than 33,000 members who have used BextraR to inform them directly about the U.S. Food and Drug Administration's FDA decision to ask that Bextra be withdrawn from the market. The FDA last Thursday concluded the overall risk versus benefit...
Tags: Aetna Inc., FDA, physician
Research articles 2005-04-11
FDA will require new Bextra warnings
Eight months after Pharmacia began marketing its new COX-2 drug Bextra valdecoxib, the FDA is requiring new warnings on the label about serious adverse effects, such as life-threatening risks related to skin reactions - including Stevens Johnson Syndrome - and anaphylactoid reactions serious allergic reactions. In addition, the labeling will...
Tags: FDA
Research articles 2003-01-01
Top NSAID Litigation Attorney James Barber Praises FDA Action on Bextra and Agency's Requirement That Warning Labels Be Placed on OTC Children's Advil and Children's Motrin; Urges Fast FDA Action To Get Labels on Products
DALLAS -- One of the country's top non-steroidal anti-inflammatory NSAID drug litigation attorneys who has fought and received settlements from the makers of Bextra and Children's Motrin on behalf of his injured clients praised the U.S. Food and Drug Administration FDA for its recent action on Bextra, but urged the...
Tags: agency, FDA
Research articles 2005-04-11
State official sues Pfizer over cost of Bextra.
Byline: Andrew Dietderich The court-appointed state official overseeing the liquidations of two bankrupt HMOs is suing Pfizer Inc. over the arthritis drug Bextra - not because of its potentially fatal side effects, but because the drug was too exp Byline: Andrew Dietderich ...
Tags: Pfizer Inc.
Research articles 2005-04-25
Pharmacia's Bextra Approved. (Markets: Life Sciences).(Brief Article)
IN THE HOTLY contested $4.3 billion COX-2 inhibitor market, Pharmacia Corp. and co-marketing partner Pfizer Inc. move ahead with Food & Drug Administration approval for its next-generation arthritis drug Bextra valedcoxib. The drug will compete against Merck & Co.'s Vioxx rofecoxib. ...
Tags: J.P. Morgan Chase & Co., Merck & Co. Inc., Pfizer Inc., Prudential Insurance Company of America, SALES, Vioxx
Research articles 2001-11-26
Research confirms health risks of Vioxx, Celebrex and Bextra
WASHINGTON AFP — New research by Wellpoint Inc., the leading US private health insurance group, has confirmed a higher risk of heart attacks with the use of painkillers such as Vioxx, Bextra and Celebrex. In a letter to the Food and Drug Administration FDA, Wellpoint director Samuel Nussbaum said...
Tags: Agence France-Presse, FDA, Government, Vioxx, WellPoint Inc.
Research articles 2005-02-16
Pfizer's Wyeth Buy Eclipses $2.3 Bill. Bextra Troubles; 19,000 Layoffs to Come
Today's announcement that Pfizer is to acquire Wyeth for $68 million eclipsed some things that on any other day would have been headline news in themselves: a) The fact that Pfizer's earnings were down 90 percent due to a $2.3 billion settlement with the Department of Justice over its off-label...
Tags: Wyeth, Layoff, Pfizer Inc., Mergers & Acquisitions, Corporate Law, Litigation, Investment, Finance, Business Operations, Jim Edwards
Blog posts 2009-01-26
Fitch: Pfizer Ratings Unaffected by Celebrex Labeling, Bextra Withdrawal
NEW YORK -- Fitch Ratings notes that the 'AAA' rating and Stable Outlook of Pfizer, Inc. PFE will not be affected by actions of the U.S. Food and Drug Administration FDA related to two leading Pfizer drugs. Yesterday, the FDA announced decisions affecting Pfizer's two Cox-2 inhibitors, Celebrex and...
Tags: FDA, Fitch Ratings, Pfizer Inc.
Research articles 2005-04-08
Pfizer Exec: Company Approved of Off-Label Bextra Promotion
Mary Holloway, the Pfizer regional manager who was sentenced last week for her role in a rogue operation that promoted Bextra for off-label uses such as post-operative pain, had the support of her superiors, she told Massachusetts federal district court. In fact, Pfizer's off-label Bextra promotion was widespread within the...
Tags: Pfizer Inc., Jim Edwards
Blog posts 2009-06-22
Pfizer's Lawyers Play Musical Chairs in Wake of Bextra Settlement
Pfizer's lawyers have found themselves playing musical chairs since the $2.3 billion Bextra settlement. The general counsel's office has been stripped of part of its compliance role under a new corporate integrity agreement with the government stemming from the Bextra scandal. More recently, senior corporate counsel Paulette Morgan left Pfizer...
Tags: Pfizer Inc., Settlement, Litigation, Government, Business Operations, Jim Edwards
Blog posts 2009-09-23
Pfizer's Off-Label Bextra Team Was Called "The Highlanders"
The Pfizer sales team leader convicted of deleting computer documents in a federal investigation of off-label Bextra and Celebrex sales called his staff "The Highlanders," according to an email produced in Massachusetts federal district court. The nickname is a reference to a movie and TV show about an immortal Scottish...
Tags: Pfizer Inc., Sales Strategy, E-mail, Leadership, Productivity, TVs, Tv & Home Theater, Sales, Online Communications, Management, Personal Technology, Home Entertainment, Jim Edwards
Blog posts 2009-06-26
Pfizer Exec Gets 6 Months' Home Confinement for Off-Label Bextra Sales
Thomas Farina, the Pfizer sales manager convicted for his role in leading "The Highlanders," a team of rogue drug reps who promoted Bextra for off-label use in Brooklyn, N.Y., was sentenced to home confinement and electronic monitoring for six months. by Jim Edwards
Tags: Pfizer Inc., Team Management, Management, Jim Edwards
Blog posts 2009-07-20
10 Amazing Facts About Pfizer's $2.3B Bextra Settlement
Here are 10 interesting facts about Pfizer's $2.3 billion settlement with the Department of Justice over its mismarketing of Bextra, the largest ever paid by a drug company for alleged violations of federal drug rules. by Jim Edwards
Tags: Pfizer Inc., Settlement, Litigation, Business Operations, Jim Edwards
Blog posts 2009-09-02
Pfizer's West Side Story: How "the Sharks" Sold Bextra Off-Label
Pfizer had a sales team in Florida that called themselves "the Sharks" as they promoted Bextra off-label, according to documents filed in the one of the cases that led to yesterday's $2.3 billion settlement. by Jim Edwards
Tags: Pfizer Inc., Sales Strategy, Litigation, Sales, Business Operations, Jim Edwards
Blog posts 2009-09-03
  • << Previous
  • page 1 of 1
  • Next >>
advertisement
advertisement
Click Here